PTAB: Success by the Numbers
Thursday, December 10th, 2015 at 10:30 am United States (GMT -07:00) Pacific
Speaker: John Callahan, partner in the Washington, DC office of Sughrue Mion
Mr. Callahan will provide a review of key aspects of successful practice before the PTAB – what do the statistics show and what does the PTAB require from a petitioner and patent owner.
This webinar is the first in Patexia's Spotlight on PTAB series, continuing with five additional speakers through March 2016.
Suggested Audience: IP practitioners working with law firms and operating companies, Companies considering using an AIA review to invalidate a patent asserted against them, licensing professionals interested in validity issues
About the Speaker
John Callahan is a partner in the firm’s Washington, DC office. He is a three-term prior member of the firm’s management committee. His practice includes all aspects of Intellectual Property law, with a particular focus on district court litigation and post-grant proceedings before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office. In addition to his litigation and practice before the PTAB, Mr. Callahan counsels a variety of international and domestic clients regarding U.S. IP law, including providing clearance, enforceability and validity opinions. He also counsels clients on licensing matters and assists clients in the procurement of both U.S. and foreign patents. Mr. Callahan’s experience includes the specialized U.S. practice of inter partes review, post grant review, ex parte reexamination, reissue and interferences.
Mr. Callahan’s practice has encompassed a wide range of technologies in the chemical, biotechnology, mechanical and electrical arts, including pharmaceuticals, food chemistry, medical devices, polymers, catalysts, glass products, semiconductor devices and electronic circuitry. Mr. Callahan has lectured widely on U.S. IP law, particularly on the USPTO's post grant procedures implemented pursuant to the America Invents Act. He has lectured in the United States, Europe, Korea, Japan, India and China on topics including strategies relating to post grant proceedings at the USPTO, what constitutes prior art under the America Invents Act, opinion writing, generic drug litigation, case law from the U.S. Court of Appeals for the Federal Circuit, claim drafting for biotech inventions, reexamination, interferences, the doctrine of equivalents and changes in U.S. patent laws and procedures.